EFFICACY AND SAFETY OF GUSELKUMAB TN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

被引：0
|
作者：
Coates, Laura C. [1 ]
Gossec, Laure [2 ]
Theander, Elke [3 ]
Bergmans, Paul [4 ]
Neuhold, Marlies [5 ]
Karyekar, Chetan S. [6 ]
Shawi, May [6 ]
Noel, Wim [5 ]
Schett, Georg [7 ]
McInnes, Iain B. [8 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[2] Sorbonne Univ, Dept Rheumatol, Paris, France
[3] Janssen Sci Affairs LLC, Dept Immunol, Solna, Sweden
[4] Janssen, Dept Biostat, Breda, Netherlands
[5] Janssen Sci Affairs LLC, Dept Immunol, Brussels, Belgium
[6] Janssen Global Serv LLC, Dept Immunol, Horsham, PA USA
[7] FAU Erlangen Nurnberg, Dept Internal Med 3, Nurnberg, Germany
[8] Univ Glasgow, Dept Immunol, Glasgow, Lanark, Scotland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2021年 / 27卷
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PANLAR2021
引用
收藏
页码：S106 / S107
页数：2
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
    Ostor, A.
    Van den Bosch, F.
    Papp, K.
    Asnal, C.
    Blanco, R.
    Aelion, J.
    Alperovich, G.
    Zhang, Y.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 138 - 139
  • [32] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
    Gratacos, Jordi
    Turkiewicz, Anthony
    Dokoupilova, Eva
    Gellett, Amanda
    Sprabery, Aubrey
    Geneus, Vladimir
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [33] Guselkumab Improves Anemia in Patients with Active Psoriatic Arthritis: Results From Two Phase 3 Randomized Controlled Clinical Trials
    Kavanaugh, Arthur
    Liu, Yang
    Rahman, Proton
    Mease, Philip
    Gossec, Laure
    Xu, Lillian
    Hsia, Elizabeth
    Shawi, May
    Han, Chenglong
    Neuhold, Marlies
    Deodhar, Atul
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 788 - 789
  • [34] Bimekizumab maintained efficacy responses through 52 weeks in patients with psoriatic arthritis and inadequate response or intolerance to tumour necrosis factor inhibitors who were responders at week 16: results from a phase 3, randomised study
    Tillett, William R.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Favalli, Ennio G.
    Mcgonagle, Dennis
    Thaci, Diamant
    Walsh, Jessica A.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Ritchlin, Christopher T.
    RHEUMATOLOGY, 2024, 63
  • [35] EARLY ONSET OF EFFICACY WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A PHASE 3B, RANDOMIZED, CONTROLLED TRIAL
    Nash, P.
    Ohson, K.
    Walsh, J.
    Delev, N.
    Nguyen, D.
    Teng, L.
    Gomez-Reino, J. J.
    Aelion, J. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 143 - 143
  • [36] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
    Deodhar, Atul
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth C.
    LANCET, 2018, 391 (10136): : 2213 - 2224
  • [37] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [38] Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naive patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study
    Ritchlin, Christopher T.
    Deodhar, Atul
    Boehncke, Wolf-Henning
    Soriano, Enrique R.
    Kollmeier, Alexa P.
    Shawi, May
    Yang, Ya-Wen
    Sheng, Shihong
    Agarwal, Prasheen
    Helliwell, Philip S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB163 - AB163
  • [39] Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
    Kavanaugh, Arthur
    Liu, Yan
    Rahman, Proton
    Mease, Philip
    Gossec, Laure
    Xu, Xie
    Hsia, Elizabeth
    Shawi, May
    Han, Chenglong
    Neuhold, Marlies
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2763 - 2766
  • [40] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BUILD STUDY
    Emery, Paul
    Krogulec, Marek
    Blanco Alonso, Ricardo
    Rossini, Maurizio
    Raeman, Frank
    Walker, David
    Ghizdavescu, Andrei Petru
    Irto, Ildiko
    Luz Rentero, Maria
    Casillas, Marta
    de la Torre, Inmaculada
    Dougados, Maxime
    RHEUMATOLOGY, 2016, 55 : 60 - 60
12345